{ "name": "State drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers", "description": "State-by-state comparison of the dollar thresholds and percentage-increase triggers that require pharmaceutical manufacturers to report drug pricing information to state regulatory agencies. As of 2026, approximately 23 US states have enacted drug price transparency laws, each with different WAC (wholesale acquisition cost) thresholds for new drugs, different percentage-increase triggers for existing drugs, different reporting timeframes, and different penalty structures. Each record is one state with its reporting thresholds. Answers 'at what price or price increase must I report in [state]', 'what is the penalty for not reporting in [state]', and 'which states require drug price transparency reporting'.", "url": "https://referencesource.org/drug-price-transparency-thresholds/", "licence": "unknown", "last_verified": "2026-08-14", "stale_after": "2027-02-10", "sources": [ "https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws", "https://dfr.oregon.gov/drugtransparency/pages/manufacturers.aspx" ], "records": [ { "state": "Connecticut", "price_increase_pct_trigger": "16% cumulative increase during the preceding two calendar years for drugs that cost $40 or more for a course of treatment", "statute_citation": "HB 6669", "id": "connecticut", "url": "https://referencesource.org/drug-price-transparency-thresholds/connecticut/", "source": "https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws", "source_quote": "HB 6669 updates the WAC increases that must be reported from a 20% WAC increase during the immediately preceding calendar year to a 16% cumulative increase during the preceding two calendar years for drugs that cost $40 or more for a course of treatment.", "verified_fields": [ "price_increase_pct_trigger", "statute_citation" ] }, { "state": "Florida", "price_increase_pct_trigger": "15% or more during the previous 12-month period or 30% or more cumulative during the preceding calendar years", "statute_citation": "Fla. Stat. \u00a7 499.026", "id": "florida", "url": "https://referencesource.org/drug-price-transparency-thresholds/florida/", "source": "https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws", "source_quote": "Fla. Stat. § 499.026 (2025), which requires drug manufacturers to report any WAC increase of 15% or more during the previous 12-month period or any cumulative WAC increase of 30% or more during the preceding calendar years.", "verified_fields": [ "price_increase_pct_trigger" ] }, { "state": "Louisiana", "new_drug_wac_threshold": "$100", "price_increase_pct_trigger": "50% for a 30-day supply", "reporting_deadline": "notification via email", "implementing_agency": "commissioner of insurance", "statute_citation": "LA. Stat. Ann. \u00a7 22:1657.1", "id": "louisiana", "url": "https://referencesource.org/drug-price-transparency-thresholds/louisiana/", "source": "https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws", "source_quote": " LA. Stat. Ann. § 22:1657.1 requires drug manufacturers to notify the commissioner of insurance if one of their drugs with a WAC 1 of $100 or more has undergone a WAC increase of 50% or more for a 30-day supply.", "verified_fields": [ "implementing_agency", "new_drug_wac_threshold", "state" ] }, { "state": "Minnesota", "generic_biosimilar_trigger": "50% over the previous 12 months", "statute_citation": "S.F. 2995", "id": "minnesota", "url": "https://referencesource.org/drug-price-transparency-thresholds/minnesota/", "source": "https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws", "source_quote": "Minnesota : S.F. 2995 amends the state’s Prescription Drug Price Transparency Act to include some technical fixes and clarifications, such as explicitly including “biosimilars” along with generic drugs in the provision that triggers reporting when there is a WAC increase of at least 50% over the previous 12 months.", "verified_fields": [ "generic_biosimilar_trigger", "state", "statute_citation" ] }, { "state": "New Jersey", "new_drug_wac_threshold": "$670 per WAC unit", "price_increase_pct_trigger": "more than 10% during any 12-month period", "generic_biosimilar_trigger": "generic drug priced at $10 or more by more than 10% during any 12-month period", "statute_citation": "NJ S.B. 1615", "id": "new-jersey", "url": "https://referencesource.org/drug-price-transparency-thresholds/new-jersey/", "source": "https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws", "source_quote": "NJ S.B. 1615 requires manufactures to report certain data points (e.g., NDC, sales volume, manufacturer costs, reasons for WAC increase) if it is increasing the WAC of a brand-name drug by more than 10% or increasing the WAC of a generic drug priced at $10 or more by more than 10% during any 12-month period. Additionally, the state requires reporting if a new drug has a WAC of $670 per WAC unit or more or a biosimilar has a WAC that is not at least 15% less than the WAC of a referenced brand biologic.", "verified_fields": [ "generic_biosimilar_trigger", "new_drug_wac_threshold", "price_increase_pct_trigger", "statute_citation" ] }, { "state": "New Mexico", "new_drug_wac_threshold": "$400 for a 30-day supply", "price_increase_pct_trigger": "10% in the previous calendar year or 16% over the previous two calendar years", "reporting_deadline": "first reporting deadline June 1, 2025", "generic_biosimilar_trigger": "30% or more over the previous calendar year", "statute_citation": "NM HB 33", "id": "new-mexico", "url": "https://referencesource.org/drug-price-transparency-thresholds/new-mexico/", "source": "https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws", "source_quote": "NM HB 33 requires drug manufacturers to report to the state data for any (1) drugs with a WAC of $400 or more for a 30-day supply, (2) course of treatment that is shorter than 30 days for a brand-name drug that has increased in WAC by 10% or more in the previous calendar year or by 16% or more over the course of the previous two calendar years, or (3) a generic drug or biosimilar that has increased in WAC by 30% or more over the previous calendar year.", "verified_fields": [ "generic_biosimilar_trigger", "price_increase_pct_trigger", "statute_citation" ] }, { "state": "New York", "price_increase_pct_trigger": "more than 16%, including the proposed increase and the cumulative increases that occurred within the prior 24 months", "reporting_deadline": "within 60 days of the planned effective date of an increase in price", "statute_citation": "NY A1707", "id": "new-york", "url": "https://referencesource.org/drug-price-transparency-thresholds/new-york/", "source": "https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws", "source_quote": "NY A1707 requires manufacturers to file a notice within 60 days of the planned effective date of an increase in price for prescription drugs with a WAC of more than $40 for a course of therapy if the increase in WAC is more than 16%, including the proposed increase and the cumulative increases that occurred within the prior 24 months.", "verified_fields": [ "price_increase_pct_trigger", "reporting_deadline", "statute_citation" ] }, { "state": "Oregon", "new_drug_wac_threshold": "$950 for a 30-day supply", "price_increase_pct_trigger": "10 percent or more", "reporting_deadline": "New drug reports due within 30 days of market entry; Annual increase reports due March 15; 60-day price increase notices due 60 days before increase", "implementing_agency": "Division of Financial Regulation", "generic_biosimilar_trigger": "25 percent or more AND the increase is $300 or more", "statute_citation": "ORS 646A.680 through 646A.692", "id": "oregon", "url": "https://referencesource.org/drug-price-transparency-thresholds/oregon/", "source": "https://dfr.oregon.gov/drugtransparency/pages/manufacturers.aspx", "source_quote": "New drug reports due within 30 days of market entry Annual increase reports due March 15 (extended to April 15, 2026 for this year) 60-day price increase notices due 60 days before increase", "verified_fields": [ "reporting_deadline" ] }, { "state": "Texas", "new_drug_wac_threshold": "$100 for a 30-day supply", "price_increase_pct_trigger": "15% or more in the previous year or 40% or more over the past three years", "implementing_agency": "Texas Health and Human Services Commission", "penalty_max": "$1,000 per day", "generic_biosimilar_trigger": "same as brand", "statute_citation": "Tex. Health & Safety Code \u00a7 441.0051-441.0054", "id": "texas", "url": "https://referencesource.org/drug-price-transparency-thresholds/texas/", "source": "https://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws", "source_quote": "15% or more in the previous year or 40% or more over the past three years. If any FDA-approved drugs are sold in Texas, the manufacturer must also submit a report with the current WAC information to the Texas Health and Human Services Commission. Penalties for noncompliance may be up to $1,000 per day from the date on which such reporting is required, after 45 days from the date the manufacturer receives notice.", "verified_fields": [ "implementing_agency", "penalty_max", "price_increase_pct_trigger", "state" ] } ] }